Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Bioengineered Human Myocardium Successfully Regenerated

By HospiMedica International staff writers
Posted on 05 Apr 2016
A new study shows that native cardiac extracellular matrix (ECM) scaffolds could support the seeding of human stem cell-derived cardiomyocytes in order to create functional myocardial-like tissue of multiple complexities.

Researchers at Massachusetts General Hospital (MGH; Boston, MA, USA) and the Harvard Stem Cell Institute (HSCI; Cambridge, MA, USA; hsci.harvard.edu) conducted a study involving 73 donated human hearts that were determined to be unsuitable for transplantation. More...
The first step involved decellularization of the hearts. A detailed characterization of the remaining cardiac scaffolds confirmed a high retention of matrix proteins, the preservation of coronary vascular and microvascular structures, and freedom from human leukocyte antigens that could induce rejection.

The ECM scaffolds were then reseeded with human cardiomyocytes derived from induced pluripotent stem cells (iPSCs), and cultured in a bioreactor that delivered a nutrient solution and replicated some of the environmental conditions that envelope a living heart. The researchers succeeded in maintaining the cardiac tissue constructs in culture for 120 days, demonstrating definitive sarcomeric structure, cell and matrix deformation, contractile force, and electrical conduction.

To show that functional myocardial tissue of human scale could be built using the platform, they then partially recellularized human whole-heart scaffolds with human induced iPSC-derived cardiomyocytes. Under the biomimetic culture, the seeded constructs developed force-generating human myocardial tissue and showed electrical conductivity, left ventricular pressure (LVP) development, and metabolic function. The study describing the process was published in the January 2016 issue of Circulation.

“Regenerating a whole heart is most certainly a long-term goal that is several years away, so we are currently working on engineering a functional myocardial patch that could replace cardiac tissue damaged due a heart attack or heart failure,” said lead author Jacques Guyette, PhD, of the MGH Center for Regenerative Medicine (CRM). “Among the next steps that we are pursuing are improving methods to generate even more cardiac cells, optimizing bioreactor-based culture techniques to improve the maturation and function of engineered cardiac tissue, and electronically integrating regenerated tissue to function within the recipient’s heart.”

Related Links:

Massachusetts General Hospital
Harvard Stem Cell Institute



Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Mobile X-Ray System
K4W
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.